On the other hand, Kadcyla® (Trastuzumab emtansine) (U.S. Food and Drug Administration (FDA), 2013) is an innovative, unique, and selective antineoplastic drug used in patients with advanced breast cancer (HER2+). Here, ERBB2 is linked to breast cancer.